Evidence map›Paper›PMID 29330698›Full record

ArticleHormones & cancer2018

Circulating Hormones and Mammographic Density in Premenopausal Women.

Kimberly A Bertrand, A Heather Eliassen, Susan E Hankinson, Bernard A Rosner, Rulla M Tamimi

Abstract read
In one paragraph

Article in Hormones & cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Other Side of the Coin: May Androgens Have a Role in Breast Cancer Risk?International journal of molecular sciences · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Kimberly A BertrandSlone Epidemiology Center at Boston University, 72 East Concord Street, L-7, Boston, MA, 02118, USA. kab15@bu.edu.
A Heather EliassenChanning Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Susan E HankinsonChanning Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Bernard A RosnerChanning Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Rulla M TamimiChanning Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Harvard University · USBoston University · USBrigham and Women's Hospital · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI Nabihah Tayob · 2013 to 2026
$30.1M
Life Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
Premonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9M
Nutritional Epidemiology of Cancer Education and Career Development ProgramR25CA098566 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI STAMPFER, MEIR · 2003 to 2013
$4.5M
Molecular Predictors of Mammographic DensityR01CA124865 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TAMIMI, RULLA M · 2008 to 2011
$1.2M
PREMENOPAUSAL HORMONE LEVELS AND RISK OF BREAST CANCERU01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1996 to 2001
$1.1M
NCI NIH HHS P01 CA087969NCI NIH HHS P50 CA168504NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA124865NCI NIH HHS R25 CA098566NCI NIH HHS U01 CA067262NCI NIH HHS U01 CA176726NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA186107
6 · The paper itself

Abstract

Prior research suggests that several endogenous hormones in premenopausal women are associated with breast cancer risk; however, few studies have evaluated associations of endogenous hormones with mammographic density (MD) in premenopausal women. We conducted a cross-sectional study of plasma hormone levels in relation to MD among 634 cancer-free premenopausal women in the Nurses' Health Study II. We measured percent MD from screening mammograms using a computer-assisted method. We assayed estradiol, estrone, and estrone sulfate in blood samples timed in early follicular and mid-luteal phases of the menstrual cycle as well as testosterone, androstenedione, progesterone, dehydroepiandrosterone (DHEA), DHEA sulfate, sex hormone-binding globulin (SHBG), and anti-Müllerian hormone in luteal or untimed samples. We used multivariable linear regression to quantify the association of %MD with quartiles of each hormone, adjusting for age, body mass index, and breast cancer risk factors. Women in the highest quartile of follicular estradiol levels had significantly greater %MD compared to those in the lowest quartile [difference, 6.7 percentage points; 95% confidence interval (CI) 2.2, 11.3; p-trend < 0.001]. Similar associations were observed for follicular free estradiol but not luteal-phase estradiol. Also, women in the top (vs. bottom) quartile of free testosterone had significantly lower %MD (difference, - 4.7; 95% CI - 8.7, - 0.8; p-trend = 0.04). Higher SHBG was significantly associated with higher percent MD (difference, 4.8; 95% CI 1.1, 8.6; p-trend = 0.002). Percent MD was not strongly associated with other measured hormones. Results were similar in analyses that excluded women with anovulatory cycles. Our findings suggest that follicular estradiol and SHBG may play an important role in premenopausal percent MD.

Indexed as

AdultBreastBreast NeoplasmsCohort StudiesEstradiolFemaleFollicular PhaseHumansImage Processing, Computer-AssistedLuteal PhaseMammographyPhenylhydrazinesPremenopauseSuccinimidesTestosteroneUnited StatesEstradiolPhenylhydrazinesSuccinimidessuccinimidyl 4-hydrazinobenzoateTestosterone

Identifiers

PMID29330698
PMCPMC5864534
OpenAlexW2783073159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.